Insulet Co. (NASDAQ:PODD) Stock Holdings Reduced by C M Bidwell & Associates Ltd.

C M Bidwell & Associates Ltd. cut its position in shares of Insulet Co. (NASDAQ:PODD) by 3.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,329 shares of the medical instruments supplier’s stock after selling 45 shares during the period. C M Bidwell & Associates Ltd.’s holdings in Insulet were worth $347,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. O Shaughnessy Asset Management LLC boosted its stake in shares of Insulet by 43.7% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 5,291 shares of the medical instruments supplier’s stock worth $1,381,000 after acquiring an additional 1,610 shares in the last quarter. IPG Investment Advisors LLC bought a new stake in Insulet during the fourth quarter worth approximately $1,496,000. Arrowstreet Capital Limited Partnership acquired a new position in Insulet during the fourth quarter valued at approximately $9,822,000. Allstate Corp bought a new position in shares of Insulet in the fourth quarter valued at approximately $545,000. Finally, DnB Asset Management AS lifted its stake in shares of Insulet by 5.7% in the fourth quarter. DnB Asset Management AS now owns 62,565 shares of the medical instruments supplier’s stock worth $16,334,000 after buying an additional 3,370 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. This represents a 36.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Insulet Price Performance

Shares of PODD opened at $258.75 on Monday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.17 billion, a PE ratio of 44.69, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The business has a 50-day simple moving average of $271.69 and a two-hundred day simple moving average of $258.97.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PODD shares. Citigroup lifted their price objective on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Piper Sandler lifted their price target on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Wells Fargo & Company increased their price objective on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.